SCHEMBL11937151

SCHEMBL11937151

COc1cccc(C(=O)/C=C/c2cccc(C)c2)c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.77
ABCG2 Q9UNQ0 1/20 0.76
BCHE P06276 1/20 0.72
P4HB P07237 1/20 0.70
CYP1A2 P05177 4/20 0.67
CYP1A1 P04798 3/20 0.67
CYP1B1 Q16678 3/20 0.67
LMNA P02545 4/20 0.66
MAPT P10636 3/20 0.66
NPC1 O15118 1/20 0.66
HTT P42858 1/20 0.66
RAB9A P51151 1/20 0.66
ALDH1A1 P00352 4/20 0.64
CYP2D6 P10635 3/20 0.64
CYP3A4 P08684 3/20 0.64
MEN1 O00255 1/20 0.64
CYP2C9 P11712 1/20 0.64
CYP2C19 P33261 1/20 0.64
KMT2A Q03164 1/20 0.64
MAOA P21397 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21002197 0.91 MAOB (0.86) MAOBABCG2BCHEP4HBCYP1A2
SCHEMBL31298986 0.91 MAOB (0.86) MAOBABCG2BCHEP4HBCYP1A2
SCHEMBL15807286 0.88 ABCG2 (0.62) MAOBABCG2BCHEP4HBCYP1A2
SCHEMBL15631514 0.87 ABCG2 (0.89) MAOBABCG2BCHEP4HBCYP1A2
SCHEMBL7771481 0.87 MAOB (0.79) MAOBABCG2BCHEP4HBCYP1A2
SCHEMBL18551752 0.87 MAOB (0.79) MAOBBCHEP4HBCYP1A2CYP1A1
SCHEMBL9341818 0.87 ABCG2 (0.89) MAOBABCG2BCHEP4HBCYP1A2
SCHEMBL7771478 0.87 MAOB (0.79) MAOBABCG2BCHEP4HBCYP1A2
SCHEMBL8987072 0.87 MAOB (1.00) MAOBABCG2BCHEP4HBCYP1A2
SCHEMBL8987069 0.87 MAOB (1.00) MAOBABCG2BCHEP4HBCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140171503-A1 NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER HUMAN SERVICES (US) 2014-06-19 US disclosed
US-8227616-B2 Cyanopyridine antibacterial agents and methods of use thereof WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2012-07-24 US disclosed
US-20100261763-A1 ANTIBACTERIAL AGENTS AND METHODS OF USE THEREOF WISCONSIN ALUMNI RESEARCH FOUNDATION 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261763-A1 ANTIBACTERIAL AGENTS AND METHODS OF USE THEREOF FDPS, CYP3A5, ABCG2 MAOB 387/4885ABCG2 3/4885BCHE 768/4885
US-20140171503-A1 NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER AR, NCOA1, NR5A1 MAOB 3966/4885ABCG2 742/4885BCHE 4460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.